This profile has not been claimed and data may not be accurate.
97th percentile
Ginkgo Bioworks co-founder and CTO scaling synthetic biology
Credibility
Traction · 97th percentile
- Ginkgo Bioworks went public via NYSE in 2021 at a ~$20B valuation.
- Raised approximately $700M in venture capital across founded companies prior to IPO.
- Ginkgo Bioworks is a publicly-traded operating company with 539 employees.
- Acquisition exit: Ginkgo acquired Warp Drive Bio.
- Acquisition exit: Ginkgo acquired Gen9.
Relationship Matrix
Most Like You
Most Complimentary
Founder score
- 98%Probability of being accurate (98%)Current co-founder and CTO of Ginkgo Bioworks.
- 97%Probability of being accurate (97%)Co-founded Ginkgo Bioworks with four MIT colleagues.
- 97%Probability of being accurate (97%)Ginkgo Bioworks was co-founded with four other MIT colleagues.
- 95%Probability of being accurate (95%)ginkgo.bio ranks #75,028 on the Majestic Million (global domain prominence).
- 95%Probability of being accurate (95%)PhD in Biological Engineering from MIT — deep domain expertise in synthetic biology.
- 95%Probability of being accurate (95%)1,445 LinkedIn followers — broad professional reach.
- 90%Probability of being accurate (90%)Ginkgo Bioworks went public via NYSE in 2021 at a ~$20B valuation.
- 85%Probability of being accurate (85%)Ginkgo Bioworks is a publicly-traded operating company with 539 employees.
- 80%Probability of being accurate (80%)Raised approximately $700M in venture capital across founded companies prior to IPO.
- 80%Probability of being accurate (80%)OpenAlex shows research credibility with 1,066 citations across 9 works on CRISPR and synthetic biology.
- 75%Probability of being accurate (75%)Acquisition exit: Ginkgo acquired Warp Drive Bio.
- 75%Probability of being accurate (75%)Acquisition exit: Ginkgo acquired Gen9.
- 70%Probability of being accurate (70%)Featured profile in Fortune covering Ginkgo Bioworks' SPAC public listing.
What you likely need
You're a deeply technical co-founder running CTO at a public synthetic-biology company with global reach, so the highest-leverage Festival events for you are small rooms with other technical CTOs of public/late-stage cos and frontier bio-AI builders. Lean into gatherings where you can swap notes on autonomous-lab automation, AI-for-bio data strategy, and recruiting senior platform engineers into Ginkgo. Boston-local sessions will also help amplify Ginkgo Cloud Lab's go-to-market.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- tacticalA small CTO roundtable with technical co-founders of other public/late-stage deep-tech companies to compare platform-engineering org structures.
- introsA bio-AI builders dinner with founders working on functional genomics, foundation models for biology, and lab automation to swap data-strategy notes for Ginkgo Datapoints.
- introsAn MIT Biological Engineering alumni-founder happy hour in Boston to deepen ties with the next generation of synbio operators.
- positioningA go-to-market workshop with developer-tools founders on positioning Ginkgo Cloud Lab to pharma R&D and academic labs.
- hiringA hiring night to recruit senior platform/automation engineers from Boston robotics and ML infra companies into Ginkgo's Nebula team.
- tacticalA post-SPAC operator dinner with CTOs/COOs of companies that went public via SPAC to share what's worked (and broken) on the path back to growth.
- tacticalAn agentic-AI demo night with builders shipping LLM-driven scientific assistants, to pressure-test Catalyst Agent's natural-language lab interface.